These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38478332)

  • 41. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
    Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
    N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
    Park JH; Rivière I; Gonen M; Wang X; Sénéchal B; Curran KJ; Sauter C; Wang Y; Santomasso B; Mead E; Roshal M; Maslak P; Davila M; Brentjens RJ; Sadelain M
    N Engl J Med; 2018 Feb; 378(5):449-459. PubMed ID: 29385376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting minimal residual disease: a path to cure?
    Luskin MR; Murakami MA; Manalis SR; Weinstock DM
    Nat Rev Cancer; 2018 Apr; 18(4):255-263. PubMed ID: 29376520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.
    Sakamuri D; Glitza IC; Betancourt Cuellar SL; Subbiah V; Fu S; Tsimberidou AM; Wheler JJ; Hong DS; Naing A; Falchook GS; Fanale MA; Cabanillas ME; Janku F
    Mol Cancer Ther; 2018 Mar; 17(3):671-676. PubMed ID: 29237802
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
    Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
    Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey.
    Su M; Zhang Q; Bai X; Wu C; Li Y; Mossialos E; Mensah GA; Masoudi FA; Lu J; Li X; Salas-Vega S; Zhang A; Lu Y; Nasir K; Krumholz HM; Jiang L
    Lancet; 2017 Dec; 390(10112):2559-2568. PubMed ID: 29102087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.
    Yu Z; Guo X; Jiang Y; Teng L; Luo J; Wang P; Liang Y; Zhang H
    Breast Cancer; 2018 Jan; 25(1):8-16. PubMed ID: 28755088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer.
    Chung W; Eum HH; Lee HO; Lee KM; Lee HB; Kim KT; Ryu HS; Kim S; Lee JE; Park YH; Kan Z; Han W; Park WY
    Nat Commun; 2017 May; 8():15081. PubMed ID: 28474673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Minimum lesion detectability as a measure of PET system performance.
    Adler S; Seidel J; Choyke P; Knopp MV; Binzel K; Zhang J; Barker C; Conant S; Maass-Moreno R
    EJNMMI Phys; 2017 Dec; 4(1):13. PubMed ID: 28260215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.
    McGranahan N; Swanton C
    Cell; 2017 Feb; 168(4):613-628. PubMed ID: 28187284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transcriptome sequencing of HER2-positive breast cancer stem cells identifies potential prognostic marker.
    Lei B; Zhang XY; Zhou JP; Mu GN; Li YW; Zhang YX; Pang D
    Tumour Biol; 2016 Nov; 37(11):14757-14764. PubMed ID: 27629143
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Busting the billion-dollar myth: how to slash the cost of drug development.
    Maxmen A
    Nature; 2016 Aug; 536(7617):388-90. PubMed ID: 27558048
    [No Abstract]   [Full Text] [Related]  

  • 53. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
    Hart T; Chandrashekhar M; Aregger M; Steinhart Z; Brown KR; MacLeod G; Mis M; Zimmermann M; Fradet-Turcotte A; Sun S; Mero P; Dirks P; Sidhu S; Roth FP; Rissland OS; Durocher D; Angers S; Moffat J
    Cell; 2015 Dec; 163(6):1515-26. PubMed ID: 26627737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dynamics of CRISPR-Cas9 genome interrogation in living cells.
    Knight SC; Xie L; Deng W; Guglielmi B; Witkowsky LB; Bosanac L; Zhang ET; El Beheiry M; Masson JB; Dahan M; Liu Z; Doudna JA; Tjian R
    Science; 2015 Nov; 350(6262):823-6. PubMed ID: 26564855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preventing clonal evolutionary processes in cancer: Insights from mathematical models.
    Rodriguez-Brenes IA; Wodarz D
    Proc Natl Acad Sci U S A; 2015 Jul; 112(29):8843-50. PubMed ID: 26195751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
    Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
    Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.
    Hoffman LM; Fouladi M; Olson J; Daryani VM; Stewart CF; Wetmore C; Kocak M; Onar-Thomas A; Wagner L; Gururangan S; Packer RJ; Blaney SM; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
    Childs Nerv Syst; 2015 Aug; 31(8):1283-9. PubMed ID: 25930724
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Translational implications of tumor heterogeneity.
    Jamal-Hanjani M; Quezada SA; Larkin J; Swanton C
    Clin Cancer Res; 2015 Mar; 21(6):1258-66. PubMed ID: 25770293
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis.
    Chen S; Sanjana NE; Zheng K; Shalem O; Lee K; Shi X; Scott DA; Song J; Pan JQ; Weissleder R; Lee H; Zhang F; Sharp PA
    Cell; 2015 Mar; 160(6):1246-60. PubMed ID: 25748654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A stress-induced early innate response causes multidrug tolerance in melanoma.
    Ravindran Menon D; Das S; Krepler C; Vultur A; Rinner B; Schauer S; Kashofer K; Wagner K; Zhang G; Bonyadi Rad E; Haass NK; Soyer HP; Gabrielli B; Somasundaram R; Hoefler G; Herlyn M; Schaider H
    Oncogene; 2015 Aug; 34(34):4448-59. PubMed ID: 25417704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.